Acurx Pharmaceuticals (ACXP) AI Stock Analysis

• Market Cap: $6.78M
• Dividend Yield: N/A
• Average Volume (3M): 93.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.30
• Revenue Growth: N/A
• EPS Growth: 53.79%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.89
• Shares Outstanding: 1,584,775
• 10 Day Avg. Volume: 133,906
• 30 Day Avg. Volume: 93,725
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.61
• 1Y Price Target: $30.50
• Price Target Upside: 612.62% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 39 Underperform
• Price Target: ―

Acurx Pharmaceuticals' score reflects the challenges of an early-stage biotech, including lack of revenue and ongoing losses, balanced by strong potential in clinical advancements and regulatory support. Technical indicators suggest weak momentum, and valuation is hindered by financial fundamentals.

Positive Factors

Regulatory Support

Regulatory alignment with FDA and EMA for Phase 3 trials enhances the likelihood of successful approval, crucial for market entry and long-term growth.

Clinical Advancements

The successful Phase 2 results with no recurrence bolster the drug's potential, supporting its progress towards commercialization and addressing antibiotic resistance.

Patent Expansion

The new patent strengthens Acurx's intellectual property portfolio, potentially opening new markets and applications, enhancing competitive positioning.

Negative Factors

Cash Position Decline

The declining cash reserves highlight financial strain, potentially limiting operational flexibility and increasing reliance on external funding.

Dependence on External Funding

Reliance on external funding for Phase 3 trials introduces uncertainty, as delays in securing funds could impact development timelines and strategic initiatives.

NASDAQ Listing Risk

Potential delisting from NASDAQ could reduce investor confidence and access to capital markets, affecting the company's financial and strategic options.

Acurx Pharmaceuticals Business Overview & Revenue Model

Company Description

Acurx Pharmaceuticals (ACXP) is a clinical-stage biopharmaceutical company focused on developing new antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, the Centers for Disease Control and Prevention, and the Food and Drug Administration. The company's lead product candidate, ibezapolstat, is designed to address the growing challenge of antibiotic resistance, specifically targeting Clostridioides difficile infections. Acurx is committed to advancing its pipeline of novel antibiotic compounds to meet the critical need for new treatments in infectious disease care.

How the Company Makes Money

Acurx Pharmaceuticals makes money primarily through the development and commercialization of its proprietary antibiotic compounds. As a clinical-stage company, its revenue model includes potential future sales of its lead product candidate, ibezapolstat, once it successfully completes clinical trials and receives regulatory approval. Additionally, Acurx may secure revenue through partnerships, licensing agreements, and collaborations with other pharmaceutical companies for the development and commercialization of its pipeline products. These partnerships could involve upfront payments, milestone payments, and royalties on sales. The company's earnings are also influenced by research grants and funding from governmental or non-governmental organizations interested in combating antibiotic-resistant infections.

Acurx Pharmaceuticals Financial Statement Overview

Summary

Acurx Pharmaceuticals exhibits characteristics typical of early-stage biotech firms, such as no revenue and ongoing net losses. However, the absence of debt and ability to secure financing are positive aspects, though risks from cash outflows remain.

Income Statement

Acurx Pharmaceuticals has consistently reported zero revenue over the years, indicating that it might still be in the development phase typical for many biotech companies. The company has incurred significant net losses, which is expected given the lack of revenue and high costs associated with R&D in this industry. However, the absence of revenue sources is a key concern.

Balance Sheet

The company's balance sheet shows no debt, which indicates conservative financial management and lowers financial risk. However, the low equity ratio and consistent equity erosion due to net losses are concerning. The company has managed to maintain a positive equity position, though it has decreased over the years.

Cash Flow

Acurx Pharmaceuticals is experiencing negative operating cash flows due to ongoing net losses, common for biotech firms without a marketable product yet. However, they have been able to secure financing to mitigate cash outflows, which is crucial for their operations. The lack of free cash flow growth is a significant downside.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-10.00M	-14.10M	-14.58M	-12.09M	-12.75M	-4.60M
Net Income	-10.00M	-14.10M	-14.58M	-12.09M	-12.75M	-4.60M
Balance Sheet
Total Assets	6.16M	3.86M	7.71M	9.38M	13.25M	3.22M
Cash, Cash Equivalents and Short-Term Investments	6.06M	3.71M	7.47M	9.11M	12.96M	3.18M
Total Debt	0.00	0.00	0.00	0.00	0.00	66.50K
Total Liabilities	2.59M	3.24M	3.04M	2.06M	843.91K	522.43K
Stockholders Equity	3.57M	615.12K	4.67M	7.32M	12.41M	2.70M
Cash Flow
Free Cash Flow	-8.16M	-10.38M	-9.80M	-7.54M	-5.01M	-3.35M
Operating Cash Flow	-8.16M	-10.38M	-9.80M	-7.54M	-5.01M	-3.35M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	7.87M	6.62M	8.16M	3.70M	14.80M	4.04M

Acurx Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACXP, the sentiment is Neutral. The current price of 4.28 is above the 20-day moving average (MA) of 4.15, below the 50-day MA of 5.10, and below the 200-day MA of 9.65, indicating a neutral trend. The MACD of -0.26 indicates Negative momentum. The RSI at 45.06 is Neutral, neither overbought nor oversold. The STOCH value of 21.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ACXP.

Acurx Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LYRA	48 Neutral	$10.69M	-0.22	-805.89%	―	-57.69%	63.76%
NURO	45 Neutral	$9.43M	-1.14	-54.54%	―	-48.61%	32.18%
ACXP	39 Underperform	$6.78M	―	-285.93%	―	―	53.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%